PT1565463E - Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona - Google Patents

Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona Download PDF

Info

Publication number
PT1565463E
PT1565463E PT03767563T PT03767563T PT1565463E PT 1565463 E PT1565463 E PT 1565463E PT 03767563 T PT03767563 T PT 03767563T PT 03767563 T PT03767563 T PT 03767563T PT 1565463 E PT1565463 E PT 1565463E
Authority
PT
Portugal
Prior art keywords
compounds
formula
imidazo
methods
mediated diseases
Prior art date
Application number
PT03767563T
Other languages
English (en)
Inventor
Fariborz Firooznia
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1565463E publication Critical patent/PT1565463E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT03767563T 2002-11-18 2003-11-17 Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona PT1565463E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42732502P 2002-11-18 2002-11-18

Publications (1)

Publication Number Publication Date
PT1565463E true PT1565463E (pt) 2008-09-10

Family

ID=32326521

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03767563T PT1565463E (pt) 2002-11-18 2003-11-17 Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona

Country Status (12)

Country Link
US (2) US7223866B2 (pt)
EP (1) EP1565463B1 (pt)
JP (1) JP2006508970A (pt)
CN (1) CN100447142C (pt)
AT (1) ATE398124T1 (pt)
AU (1) AU2003292039A1 (pt)
BR (1) BR0316306A (pt)
CA (1) CA2505752A1 (pt)
DE (1) DE60321593D1 (pt)
ES (1) ES2305520T3 (pt)
PT (1) PT1565463E (pt)
WO (1) WO2004046145A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1569896T3 (da) * 2002-12-06 2007-12-10 Xention Ltd Tetrahydronaphthalenderivater
US7544716B2 (en) 2002-12-09 2009-06-09 Xention Limited Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
JP5612860B2 (ja) * 2007-03-09 2014-10-22 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体
EP2209780B1 (en) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
MX2011012628A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
ES2582395T3 (es) 2009-05-28 2016-09-12 Novartis Ag Derivados aminobutíricos sustituidos como inhibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN102666535B (zh) * 2009-11-30 2015-02-25 诺华股份有限公司 作为醛固酮合酶抑制剂的咪唑衍生物
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
PL2729142T3 (pl) 2011-07-08 2018-10-31 Novartis Ag Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2757883B1 (en) 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
EP2757884B1 (en) 2011-09-22 2022-07-27 Merck Sharp & Dohme LLC Pyrazolopyridyl compounds as aldosterone synthase inhibitors
PL2804863T3 (pl) 2012-01-17 2016-06-30 Novartis Ag Nowe postacie i sole inhibitora syntazy aldosteronowej lub aromatazy dihydropirolo[1,2-c]imidazolilu
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
WO2016116842A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
GB201511790D0 (en) * 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
KR20260015867A (ko) 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101595B (en) * 1981-06-22 1985-05-30 Ciba Geigy Ag Substituted imidazo(1,5-a)pyridines, process for their manufacture, pharmaceutical preparations containing these compounds and their therapeutic application
US4470986A (en) * 1982-12-21 1984-09-11 Ciba-Geigy Corporation Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors
US5428160A (en) * 1982-12-21 1995-06-27 Ciba-Geigy Corporation Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives
US4588732A (en) * 1982-12-21 1986-05-13 Ciba-Geigy Corporation Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
JPS615076A (ja) * 1984-06-19 1986-01-10 Toyama Chem Co Ltd 新規な１，４−ジヒドロピリジン誘導体およびその塩
GB8510541D0 (en) * 1985-04-25 1985-05-30 Wyeth John & Brother Ltd Heterocyclic compounds
US5798364A (en) 1992-03-26 1998-08-25 Merck Patent Gesellschaft Mit Beschrankter Haftung Imidazopyridines
US6150347A (en) 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US5529992A (en) 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
JPH0971586A (ja) 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
DE19701257A1 (de) * 1997-01-17 1998-07-23 Hannecke Wolf D Kunststoff Säulenpräsentationssystem in Modulbauweise zur Schaustellung von Waren oder Prospektmaterial und insbesondere von dünnen Gegenständen
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method

Also Published As

Publication number Publication date
EP1565463B1 (en) 2008-06-11
DE60321593D1 (de) 2008-07-24
JP2006508970A (ja) 2006-03-16
CN100447142C (zh) 2008-12-31
US20070197582A1 (en) 2007-08-23
WO2004046145A1 (en) 2004-06-03
CA2505752A1 (en) 2004-06-03
ATE398124T1 (de) 2008-07-15
HK1081540A1 (en) 2006-05-19
US20060058342A1 (en) 2006-03-16
BR0316306A (pt) 2005-09-27
AU2003292039A1 (en) 2004-06-15
EP1565463A1 (en) 2005-08-24
US7713991B2 (en) 2010-05-11
US7223866B2 (en) 2007-05-29
ES2305520T3 (es) 2008-11-01
CN1711262A (zh) 2005-12-21

Similar Documents

Publication Publication Date Title
PT1565463E (pt) Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona
EP1537114B8 (en) Organic compounds as agents for the treatment of aldosterone mediated conditions
WO2008076336A3 (en) Imidazoles as aldosterone synthase inhibitors
WO2007117982A3 (en) Organic compounds
WO2007024945A8 (en) Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
WO2009079412A3 (en) Reverse transcriptase inhibitors
GB2396864B (en) RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression
DE60324183D1 (en) Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
MY121399A (en) Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
WO2004020410A3 (en) Dihydropyridinone derivatives as hne inhibitors
WO2004052855A3 (en) Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
TW200503730A (en) Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
UY25321A1 (es) Combinaciones de inhibidor de ace-inhibidor de mmp
UA84453C2 (ru) Применение производных метиленамида для лечения сердечно-сосудистых заболеваний
AU2001296821A1 (en) Methods of inhibiting angiogenesis using nadph oxidase inhibitors
WO2006071644A8 (en) Selective inhibitors of erk protein kinases and uses therof
TW200635932A (en) New pyridothienopyrimidine derivatives
TW200631954A (en) New pyridothienopyrimidine derivatives
NO20060247L (no) Substituerte spirobenzazepiner
ATE310005T1 (de) 1- oder 3-thia-benzonaphthoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
ZA200609946B (en) Adamantyl-acetamide derivatives as inhibitor of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
TW200736264A (en) Thiazolo[4,5-C]pyridine derivatives
WO2007124355A3 (en) Vascular endothelial receptor specific inhibitors
IL164397A0 (en) 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates forthe production thereof
DE602004021145D1 (de) NEUE SUBSTITUIERTE THIOPHENPYRIMIDINONDERIVATE ALS INHIBITOREN VON 17ß-HYDROXYSTEROIDDEHYDROGENASE